Pathophysiology of sepsis

被引:401
作者
Remick, Daniel G. [1 ]
机构
[1] Boston Univ, Sch Med, Boston, MA 02215 USA
关键词
D O I
10.2353/ajpath.2007.060872
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Sepsis remains a critical problem with significant morbidity and mortality even in the modern era of critical care management. Multiple derangements exist in sepsis involving several different organs and systems, although controversies exist over their individual contribution to the disease process. Septic patients have substantial, life-threatening alterations in their coagulation system, and currently, there is an approved therapy with a component of the coagulation system (activated protein Q to treat patients with severe sepsis. Previously, it was believed that sepsis merely represented an exaggerated, hyperinflammatory response with patients dying from inflammation-induced organ injury. More recent data indicate that substantial heterogeneity exists in septic patients' inflammatory response, with some appearing immuno-stimulated, whereas others appear suppressed. Cellular changes continue the theme of heterogeneity. Some cells work too well such as neutrophils that remain activated for an extended time. Other cellular changes become accelerated in a detrimental fashion including lymphocyte apoptosis. Metabolic changes are clearly present, requiring close and individualized monitoring. At this point in time, the literature richly illustrates that no single mediator/systenx/pathway/pathogen drives the pathophysiology of sepsis. This review will briefly discuss many of the important alterations that account for the pathophysiology of sepsis.
引用
收藏
页码:1435 / 1444
页数:10
相关论文
共 85 条
[21]   Effect of a chimeric antibody to tumor necrosis factor-α on cytokine and physiologic responses in patients with severe sepsis -: A randomized, clinical trial [J].
Clark, MA ;
Plank, LD ;
Connolly, AB ;
Streat, SJ ;
Hill, AA ;
Gupta, R ;
Monk, DN ;
Shenkin, A ;
Hill, GL .
CRITICAL CARE MEDICINE, 1998, 26 (10) :1650-1659
[22]   Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit [J].
Clayton, Stephanie B. ;
Mazur, Joseph E. ;
Condren, Stacey ;
Hermayer, Kathie L. ;
Strange, Charlie .
CRITICAL CARE MEDICINE, 2006, 34 (12) :2974-2978
[23]   INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].
Cohen, J ;
Carlet, J .
CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440
[24]   Acute inflammatory response to endotoxin in mice and humans [J].
Copeland, S ;
Warren, HS ;
Lowry, SF ;
Calvano, SE ;
Remick, D .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (01) :60-67
[25]   CDP571, A HUMANIZED ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA - SAFETY, PHARMACOKINETICS, IMMUNE-RESPONSE, AND INFLUENCE OF THE ANTIBODY ON CYTOKINE CONCENTRATIONS IN PATIENTS WITH SEPTIC SHOCK [J].
DHAINAUT, JFA ;
VINCENT, JL ;
RICHARD, C ;
LEJEUNE, P ;
MARTIN, C ;
FIEROBE, L ;
STEPHENS, S ;
NEY, UM ;
SOPWITH, M ;
MERCAT, A ;
EDOUARD, A ;
FRIEDMAN, G ;
MARIN, N ;
SCHLEMMER, B ;
LEPAPE, A ;
NOVAK, C .
CRITICAL CARE MEDICINE, 1995, 23 (09) :1461-1469
[26]   Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment [J].
Docke, WD ;
Randow, F ;
Syrbe, U ;
Krausch, D ;
Asadullah, K ;
Reinke, P ;
VolK, HD ;
Kox, W .
NATURE MEDICINE, 1997, 3 (06) :678-681
[27]  
DRIES DJ, 1994, ARCH SURG-CHICAGO, V129, P1031
[28]   Surviving sepsis - Practice guidelines, marketing campaign, and Eli Lilly [J].
Eichacker, Peter Q. ;
Natanson, Charles ;
Danner, Robert L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (16) :1640-1642
[29]  
Esmon C T, 1987, Dev Biol Stand, V67, P51
[30]   Inflammation and the activated protein C anticoagulant pathway [J].
Esmon, Charles T. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 :49-60